이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Caplin Point Laboratories 관리

관리 기준 확인 3/4

Caplin Point Laboratories' CEO는 Sridhar Ganesan, Mar2015 에 임명되었습니다 의 임기는 9.25 년입니다. 총 연간 보상은 ₹ 8.70M, 95.4% 로 구성됩니다. 95.4% 급여 및 4.6% 보너스(회사 주식 및 옵션 포함). 는 ₹ 127.59M 가치에 해당하는 회사 주식의 0.12% 직접 소유합니다. 127.59M. 경영진과 이사회의 평균 재임 기간은 각각 8.3 년과 5.9 년입니다.

주요 정보

Sridhar Ganesan

최고 경영자

₹8.7m

총 보상

CEO 급여 비율	95.4%
CEO 임기	9.3yrs
CEO 소유권	0.1%
경영진 평균 재임 기간	8.4yrs
이사회 평균 재임 기간	6yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Sridhar Ganesan 의 보수는 Caplin Point Laboratories 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Mar 31 2024	n/a	n/a	₹5b
Dec 31 2023	n/a	n/a	₹4b
Sep 30 2023	n/a	n/a	₹4b
Jun 30 2023	n/a	n/a	₹4b
Mar 31 2023	₹9m	₹8m	₹4b
Dec 31 2022	n/a	n/a	₹4b
Sep 30 2022	n/a	n/a	₹3b
Jun 30 2022	n/a	n/a	₹3b
Mar 31 2022	₹6m	₹5m	₹3b
Dec 31 2021	n/a	n/a	₹3b
Sep 30 2021	n/a	n/a	₹3b
Jun 30 2021	n/a	n/a	₹3b
Mar 31 2021	₹6m	₹5m	₹2b
Dec 31 2020	n/a	n/a	₹2b
Sep 30 2020	n/a	n/a	₹2b
Jun 30 2020	n/a	n/a	₹2b
Mar 31 2020	₹6m	₹6m	₹2b
Dec 31 2019	n/a	n/a	₹2b
Sep 30 2019	n/a	n/a	₹2b
Jun 30 2019	n/a	n/a	₹2b
Mar 31 2019	₹6m	₹6m	₹2b
Dec 31 2018	n/a	n/a	₹2b
Sep 30 2018	n/a	n/a	₹2b
Jun 30 2018	n/a	n/a	₹1b
Mar 31 2018	₹6m	₹6m	₹1b

보상 대 시장: Sridhar 의 총 보상 ($USD 104.19K ) Indian 시장에서 비슷한 규모의 회사에 대한 평균보다 낮습니다( $USD 438.56K ).

보상과 수익: Sridhar 의 보상은 지난 1년 동안 20% 이상 증가했습니다.

CEO

Sridhar Ganesan (69 yo)

9.3yrs

테뉴어

₹8,700,000

보상

Dr. Sridhar Ganesan has been the Managing Director of Caplin Point Laboratories Ltd since March 28, 2015. Dr. Ganesan has been Whole Time Director of Caplin Point Laboratories Ltd since August 25, 2014. He...

리더십 팀

이름	위치	테뉴어	보상	소유권
Sridhar Ganesan	MD & Whole Time Director	9.3yrs	₹8.70m	0.12% ₹ 130.2m
D. Muralidharan	Chief Financial Officer	8.4yrs	₹9.70m	0.020% ₹ 21.7m
Partheeban Siddarth	Chief Operating Officer	12.9yrs	₹1.90m	11.84% ₹ 12.9b
G. Venkatram	General Counsel	1.9yrs	₹2.30m	데이터 없음
M. Narayanan	Deputy Chief Financial Officer	no data	데이터 없음	데이터 없음
Ashok Partheeban	Head of Marketing - Latam Business	no data	데이터 없음	11.91% ₹ 12.9b
Thiagaraja Manikandan	Chief Transformation & Digital Officer	less than a year	데이터 없음	데이터 없음

8.4yrs

평균 재임 기간

경험이 풍부한 관리: 524742 의 관리팀은 노련하고 경험 (평균 재직 기간 8.3 년)입니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Sridhar Ganesan	MD & Whole Time Director	10.4yrs	₹8.70m	0.12% ₹ 130.2m
Paarthipan Chellappan	Non-Executive Non-Independent Chairman	34.3yrs	데이터 없음	18.64% ₹ 20.3b
Damodaran Sathyanarayanan	Non-Executive Independent Director	7.7yrs	₹160.00k	데이터 없음
Chanderkanta Gariyali	Non-Executive Independent Director	4.3yrs	₹100.00k	데이터 없음
R. Nagendran	Non-Executive Independent Director	1.8yrs	₹40.00k	데이터 없음
S. Deenadayalan	Independent Non-Executive Director	1.8yrs	₹60.00k	0.000090% ₹ 97.8k

6.0yrs

평균 재임 기간

71.5yo

평균 연령

경험이 풍부한 이사회: 524742 의 이사회는 경험(평균 재직 기간 5.9 년)으로 간주됩니다.

Caplin Point Laboratories 관리

관리 기준 확인 3/4

주요 정보

최근 관리 업데이트

Caplin Point Laboratories Limited Appoints Thiagaraja Manikandan as Chief Transformation & Digital Officer

Caplin Point Laboratories Limited, Annual General Meeting, Sep 21, 2023

Caplin Point Laboratories Limited Announces Change in Directorate

Caplin Point Laboratories Limited, Annual General Meeting, Sep 29, 2022

Caplin Point Laboratories Limited, Annual General Meeting, Sep 29, 2022

Caplin Point Laboratories Limited Announces Resignation of D P Mishra as Non-Executive, Non-Independent Director

Recent updates

Caplin Point Laboratories Limited Appoints Thiagaraja Manikandan as Chief Transformation & Digital Officer

Investor sentiment improves as stock rises 17%

Full year 2024 earnings: Revenues in line with analyst expectations

Caplin Point Laboratories Limited Declares an Interim Dividend for the Financial Year Ended March 31, 2024

Caplin Point Laboratories Limited to Report Fiscal Year 2024 Results on May 16, 2024

Third quarter 2024 earnings released: EPS: ₹15.44 (vs ₹12.86 in 3Q 2023)

Caplin Point Laboratories Limited to Report Q3, 2024 Results on Feb 09, 2024

Investor sentiment improves as stock rises 17%

Price target increased by 8.0% to ₹1,076

Second quarter 2024 earnings released: EPS: ₹15.13 (vs ₹12.09 in 2Q 2023)

Caplin Point Laboratories Limited to Report Q2, 2024 Results on Nov 09, 2023

Caplin Point Laboratories Limited Approves Final Dividend for the Year Ended March 31, 2023

Upcoming dividend of ₹2.50 per share at 0.5% yield

Caplin Point Laboratories Limited, Annual General Meeting, Sep 21, 2023

Consensus EPS estimates increase by 12%

Investor sentiment improves as stock rises 15%

Caplin Point Laboratories Limited Recommends Final Dividend for the Financial Year Ended March 31, 2023

First quarter 2024 earnings released: EPS: ₹13.62 (vs ₹11.21 in 1Q 2023)

Caplin Point Laboratories Limited to Report Q1, 2024 Results on Aug 07, 2023

Caplin Steriles Limited Gets United States Food and Drug Administration Approval for Cisatracurium Besylate Injection USP

Consensus EPS estimates increase by 12%

Upcoming dividend of ₹2.00 per share at 0.3% yield

Full year 2023 earnings: EPS exceeds analyst expectations

Caplin Point Laboratories Limited to Report Q4, 2023 Results on May 24, 2023

Now 20% undervalued after recent price drop

Third quarter 2023 earnings released: EPS: ₹12.86 (vs ₹9.90 in 3Q 2022)

Caplin Point Laboratories Limited to Report Q3, 2023 Results on Feb 11, 2023

Price target increased to ₹948

Second quarter 2023 earnings released: EPS: ₹12.09 (vs ₹9.91 in 2Q 2022)

Caplin Point Laboratories Limited (BSE:524742) acquired API plant in Vizag from Metrochem API Private Limited.

Second quarter 2023 earnings released: EPS: ₹12.09 (vs ₹9.91 in 2Q 2022)

Caplin Point Laboratories Limited to Report Q2, 2023 Results on Nov 12, 2022

Caplin Point Laboratories Limited Approves Final Dividend for the Financial Year Ended March 31, 2022

Caplin Point Laboratories Limited Announces Change in Directorate

Upcoming dividend of ₹2.00 per share

Caplin Point Laboratories Limited, Annual General Meeting, Sep 29, 2022

Caplin Point Laboratories Limited, Annual General Meeting, Sep 29, 2022

Caplin Point Laboratories Limited Recommends Final Dividend for the Financial Year Ended March 31, 2022

First quarter 2023 earnings released: EPS: ₹11.21 (vs ₹9.37 in 1Q 2022)

Caplin Point Laboratories Limited to Report Q1, 2023 Results on Aug 05, 2022

Caplin Point Laboratories Limited Announces Resignation of D P Mishra as Non-Executive, Non-Independent Director

Investor sentiment improved over the past week

Upcoming dividend of ₹2.00 per share

Full year 2022 earnings: Revenues and EPS in line with analyst expectations

Caplin Point Laboratories Limited Approves Interim Dividend for the Financial Year Ended March 31, 2022

Caplin Point Laboratories Limited to Report Fiscal Year 2022 Results on May 12, 2022

Insufficient new directors

Investor sentiment deteriorated over the past week

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Caplin Point Laboratories Limited to Report Q3, 2022 Results on Feb 03, 2022

Insufficient new directors

Insider recently sold ₹4.3m worth of stock

Second quarter 2022 earnings released: EPS ₹9.91 (vs ₹7.52 in 2Q 2021)

Upcoming dividend of ₹1.50 per share

Investor sentiment improved over the past week

First quarter 2022 earnings released: EPS ₹9.37 (vs ₹7.21 in 1Q 2021)

Investor sentiment improved over the past week

Non-Executive Independent Director has left the company

Upcoming dividend of ₹1.50 per share

Full year 2021 earnings released: EPS ₹32.03 (vs ₹28.42 in FY 2020)

Caplin Point Laboratories Limited Declares Interim Dividend for the Financial Year Ended March 31, 2021

Investor sentiment improved over the past week

Investor sentiment improved over the past week

New 90-day low: ₹457

Company Secretary & Compliance Officer has left the company

Caplin Point Laboratories Limited Announces Executive Changes

Third quarter 2021 earnings released: EPS ₹8.52 (vs ₹7.74 in 3Q 2020)

Revenue and earnings beat expectations

Revenue beats expectations, earnings disappoint